Delving into the Latest Updates on Epidermal growth factor cancer vaccine(Center of Molecular Immunology) with Synapse

Overview

Basic Info

Drug Type

Therapeutic vaccine

Synonyms

CIMAv, CIMAvax Epidermal Growth Factor Vaccine, CIMAvax IM

+ [15]

Target

EGF

Mechanism

EGF inhibitors(Epidermal growth factor inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersRespiratory Diseases+ [1]

Active Indication

Colorectal CancerNon-Small Cell Lung CancerProstatic Cancer+ [1]

Inactive Indication-

Originator Organization

Center For Molecular Immunology

Active Organization

Center For Molecular Immunology

Inactive Organization

In3Bio Research Ltd.Bioven Sdn. Bhd.

Drug Highest PhaseApproved

First Approval Date

CU (01 Jun 2008),

Colorectal CancerNon-Small Cell Lung CancerProstatic Cancer+ [1]

Regulation-

Login to view timeline

The purpose of this study is to determine the immunogenicity of the CIMAvaxEGF® vaccine (that is, its effectiveness in inducing an anti-tumor immune response) in patients with metastatic KRAS/NRAS/BRAF wild-type gene colorectal cancer, when given in combination with standard therapies used in the treatment of advanced colorectal cancer.

Start Date04 Dec 2023

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

RPCEC00000375 / SuspendedPhase 2

Safety and effect of CIMAvax-EGF® in convalescent patients from SARS-CoV-2 infection with respiratory disorders. Phase II (COVID-19) - CORVAXCIM

Start Date25 Dec 2021

Sponsor / Collaborator

Center For Molecular Immunology

100 Clinical Results associated with Epidermal growth factor cancer vaccine(Center of Molecular Immunology)

Login to view more data

100 Translational Medicine associated with Epidermal growth factor cancer vaccine(Center of Molecular Immunology)

Login to view more data

100 Patents (Medical) associated with Epidermal growth factor cancer vaccine(Center of Molecular Immunology)

Login to view more data

40

Literatures (Medical) associated with Epidermal growth factor cancer vaccine(Center of Molecular Immunology)

01 May 2024·Journal of Endodontics

Comparative Analysis of Irrigation Techniques for Cleaning Efficiency in Isthmus Structures

Article

Author: Dust, Patricia Claire ; Donnermeyer, David ; Schäfer, Edgar ; Bürklein, Sebastian

INTRODUCTIONThis study aimed to evaluate the removal of a biofilm-mimicking hydrogel from isthmus structures in a simulated complex root canal system consisting of 2 curved root canals by Laser-activated irrigation (LAI, AdvErl Evo, Morita) and mechanical activation techniques.METHODSA 3D-printed root canal model with 2 parallel root canals (60°-curvature, radius 5 mm, dimension 25/.06) with a total length of 20 mm connected via isthmuses (2.5 × 0.4 × 0.2 mm) at 5 mm and 8 mm from the apical endpoint and with lateral canals (diameter 0.2 mm) in all directions at 2, 5, and 8 mm from the apex was filled with a colored biofilm-mimicking hydrogel. Irrigation protocols under continuous irrigation with distilled water (3 × 20s per root canal; 3 ml/20s; n = 20) included conventional needle irrigation (=NI); manual agitation (=MA, gutta-percha point 25/.06); EndoActivator (=SAI-EA, 25/.04); EDDY (=SAI-E, 25/.04); ultrasonically-activated irrigation (=UAI) and LAI (Er:YAG-laser; P400FL tip at canal entrance; 25pps, 50 mJ, 300μs). Removal of the hydrogel was determined as a percentage via standardized photos through a microscope. Statistical analysis was performed using Kruskal-Wallis and Conover tests (P = .05).RESULTSLaser-activated irrigation (LAI) was associated with the greatest removal of hydrogel from the entire root canal system (P < .05), followed by SAI-E. No significant differences were reported for the coronal isthmus between LAI, SAI-E, NI, and MA (P > .05), but inferior results for SAI-EA and UAI (P < .05). In the apical isthmus, all techniques outperformed UAI (P < .05), with LAI, SAI-E, and NI showing the best results (P < .05).CONCLUSIONSLaser-activated irrigation (LAI) was superior to other irrigation techniques in the entire root canal system. SAI-E and NI performed comparable to LAI in the isthmuses.

01 Nov 2023·Journal of Endodontics

Cleaning Efficiency of Different Irrigation Techniques in Simulated Severely Curved Complex Root Canal Systems

Article

Author: Schäfer, Edgar ; Donnermeyer, David ; Bürklein, Sebastian ; Averkorn, Christin

INTRODUCTIONTo compare the biofilm-mimicking hydrogel removal efficiency of laser-activated irrigation (LAI) with five other irrigation techniques in simulated curved root canals with lateral canals.METHODSThree-dimensional-printed root canal models (60°-curvature, radius 5 mm; dimension 25/.06) with a total length of 20 mm and lateral canals in all directions at 2, 5, and 8 mm (diameter 0.2 mm) from the apex were filled with a colored biofilm-mimicking hydrogel. The following protocols (each 3 × 20 seconds continuous irrigation with distilled water 3 ml/20 seconds; n = 20) were carried out: conventional needle irrigation; manual agitation ([MA], gutta-percha point 25/.06); EndoActivator (=sonically-activated irrigation EndoActivator, 25/.04); EDDY (=sonically-activated irrigation EDDY [SAI-E]; 25/.04); ultrasonically-activated irrigation and LAI (Erbium-doped Yttrium Aluminum Garnet laser; P400FL tip at canal entrance; 25 pps, 50 mJ, 300 μs). Standardized photos were taken with a microscope and the removal of the hydrogel was determined as a percentage for the entire system, the main canal and the lateral canals. Statistical analysis was performed using analysis of variance and Scheffé test (P = .05).RESULTSLAI (89.3% ± 5.9%) showed the greatest hydrogel removal followed by SAI-E (65.5% ± 3.3%) and ultrasonically-activated irrigation (59.1% ± 4.7%), with significant differences between these groups (P < .05). Needle irrigation, MA, and sonically-activated irrigation EndoActivator performed equally (P > .05) and obtained the significantly lowest values (P < .05). LAI and SAI-E showed the significantly best hydrogel removal from the main canal (P < .05). At all three levels, LAI removed significantly more hydrogel from the lateral canals than all other techniques (P < .05).CONCLUSIONSLAI was superior to other techniques in both the entire system and the lateral canals in removing the hydrogel. SAI-E achieved comparable results in the main canal.

01 Jan 2023·Journal of Cancer

Survival of NSCLC Patients Treated with Cimavax-EGF as Switch Maintenance in the Real-World Scenario.

Article

Author: Gracia Medina, Elias A ; Alsina Sarmiento, Sofía C ; Rodríguez Machado, Jorge ; Elejalde Larrinaga, Ángel ; Páramo González, Diana L ; Crombet Ramos, Tania ; Flores Vega, Yoanna I ; Lamadrid García, Janet ; Ropero Toirac, Ramón ; Corrales Otero, Danay ; Flores Rodríguez, Justo E ; Alsina Tul, Luis E ; Inguanzo Valdés, Iris B

Introduction: In Cuba, lung cancer represents the first cause of mortality for both sexes. Non-small cell lung cancer (NSCLC) is the most prevalent histology. Overall, 75-85% of NSCLC overexpress EGFR and its ligands. EGFR overexpression has been implicated in the malignant transformation by promoting cell proliferation and survival. CIMAvax-EGF is a therapeutic vaccine composed of recombinant-human EGF conjugated to a carrier protein and Montanide as an adjuvant. CIMAvax-EGF is intended to induce antibodies against self-EGF that block the EGF-EGFR interaction. Objectives: To characterize the efficacy and safety of CIMAvax-EGF as maintenance in NSCLC patients treated in the real-world setting. Results: 106 patients diagnosed with advanced NSCLC at the National Institute of Oncology and Radiobiology, who had at least stable disease after first-line therapy, were enrolled in the study. The initial four CIMAvax-EGF doses were administered every 2 weeks and then, patients received monthly re-immunizations. Globally, 52.8% of the patients were 65 years or older, 77.4% had an ECOG 1 and 62.3% had an adenocarcinoma. The median survival time (MST) was 14.6 months. Patients younger than 65 years had a MST of 16.7 months and subjects with ECOG 0 survived for 29 months. The median progression-free survival was 8.16 months. Overall, 36.8% and 19.8% of patients maintained disease control at 6 and 12 months, respectively. The most frequent adverse events were pain (27.3%) or induration (7.3%) at the injection site and local erythema (10.9%). Conclusion: CIMAvax-EGF, as an EGF depleting immunotherapy used as switch-maintenance was safe and effective in patients with NSCLC.

100 Deals associated with Epidermal growth factor cancer vaccine(Center of Molecular Immunology)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Epidermal growth factor cancer vaccine(Center of Molecular Immunology)	J07X	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Colorectal Cancer	CU	-	01 Jun 2008
Non-Small Cell Lung Cancer	CU	-	01 Jun 2008
Prostatic Cancer	CU	-	01 Jun 2008
Stomach Cancer	CU	-	01 Jun 2008

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 2	MY	Bioven Sdn. Bhd.	01 Jul 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02955290 (ASCO2023) Manual	Phase 2	Advanced Lung Non-Small Cell Carcinoma Second line	21	Nivolumab+CIMAvax-EGF	(yfjfxjddqk) = nkmqmuzzei mjoamjrhhy (ufqlhgcyvt, 14 - 45) View more	Positive	31 May 2023
NCT02955290 (ASCO2023) Manual	Phase 2	Advanced Lung Non-Small Cell Carcinoma Second line	21	Nivolumab+CIMAvax-EGF ( PD-L1 expression ≥1% )	(yfjfxjddqk) = sjpywnbumh mjoamjrhhy (ufqlhgcyvt, 12 - 63) View more	Positive	31 May 2023
RPCEC00000205 (ESMO2022)	Phase 4	Non-Small Cell Lung Cancer	741	CIMAvax-EFG (EGF concentrations <870 pg/mL)	(vwozqlxsie) = iqnzbzswsl teyhowjjzn (ffnomxecya ) View more	-	10 Sep 2022
RPCEC00000205 (ESMO2022)	Phase 4	Non-Small Cell Lung Cancer	741	CIMAvax-EFG (EGF concentrations ≥870 pg/mL)	(vwozqlxsie) = sgfpocrbjx teyhowjjzn (ffnomxecya ) View more	-	10 Sep 2022
NCT02455557 (CTgov)	Phase 2	Gliosarcoma \| Glioblastoma	66	Laboratory Biomarker Analysis+Temozolomide+Montanide ISA 51 VG+Sargramostim+SVN53-67/M57-KLH Peptide Vaccine	bvcqogzjnh(ptqsogmuag) = fxrhzwtpfv joimasetnl (jwamkbjnhy, bzaxfjjclz - sdfuvnftqv) View more	-	01 Feb 2021
WCLC2019	Not Applicable	Maintenance	106	CIMAvax-EGF vaccine	uagwdimqfk(mzqbpqvwgt) = 7.3% ytblxmhajs (cyelwdlxax ) View more	-	09 Sep 2019
WCLC2019	Not Applicable	Non-small cell lung cancer stage III First line	-	Cimavax-EGF	(jxyajnublg) = qrkohwoaov qoazlfzzxm (qduxprzswv ) View more	-	09 Sep 2019
WCLC2018	Not Applicable	Advanced Lung Non-Small Cell Carcinoma Second line	9	CIMAvax-EGF	(bcyxwngemu) = aqfyqriyag jdblwqsuur (jqpszrzuvc )	-	25 Sep 2018
ASCO2012	Phase 2	metastatic non-small cell lung cancer First line	12	Anti-EGF vaccine alone	(olewrmctni) = 42.4% ypohgdbroc (wpejfsjtos ) View more	Positive	20 May 2012